Search

Incyte Corp

Atidarymo kaina

SektoriusSveikatos priežiūra

124.32 2.22

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

121

Max

123.93

Pagrindiniai rodikliai

By Trading Economics

Pajamos

282M

586M

Pardavimai

401M

1.7B

P/E

Sektoriaus vid.

15.566

56.432

Pelnas, tenkantis vienai akcijai

2.8

Pelno marža

34.982

Darbuotojai

2,844

EBITDA

384M

752M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+7.43% upside

Dividendai

By Acuity

Kitas uždarbis

2026-10-27

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1B

25B

Ankstesnė atidarymo kaina

122.1

Ankstesnė uždarymo kaina

124.32

Naujienos nuotaikos

By Acuity

57%

43%

267 / 339 reitingas Healthcare

Incyte Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-15 23:06; UTC

Incyte Corp shares are trading lower in after-market hours, reflecting broader market fluctuations and remaining below the 20-day moving average.

2026-09-14 20:08; UTC

Incyte Corp's shares are higher amid overall market gains, despite earlier volatility. Broader market concerns include rising crude oil prices and inflation.

2026-09-11 22:01; UTC

Incyte Corp shares are higher in after-market trading, despite a decline in consumer sentiment reflected by the Michigan Consumer Sentiment Index.

2026-09-10 19:36; UTC

Event
News

Incyte's MINJUVI receives funding in Ontario for lymphoma treatment. Shares are lower despite this development, currently trading below their 20-day moving average.

2026-09-09 19:07; UTC

Event
Social Media

Incyte Corp gains amid positive sentiment for its upcoming PDUFA date for Zilurgisertib, scheduled for September 26, despite earlier session volatility.

2026-09-08 20:02; UTC

News

Incyte Corp shares are lower today, driven by a downturn in the Biotechnology sub-sector. Analysts maintain a consensus "Moderate Buy" rating on the stock.

2026-09-04 23:55; UTC

Incyte Corp shares are higher in after-market hours, reaching an early peak before settling back. No specific news was identified to explain the movement.

2026-09-03 19:16; UTC

Incyte Corp shares are lower amid broader market declines influenced by rising jobless claims. The stock remains above its 20-day moving average.

2026-09-02 23:16; UTC

Incyte Corp shares are trading higher in after-market hours, amid a weaker-than-expected ADP payrolls report that may influence Federal Reserve interest rate decisions.

2026-09-01 22:06; UTC

Incyte Corp shares are higher in after-market hours, though no specific news explains the movement. Broader market pressures persist from rising bond yields.

2026-08-31 20:04; UTC

News

Incyte Corp shares are lower amid broader market weakness following comments from Warsh at the Jackson Hole Economic Symposium on inflation and monetary policy.

2026-08-28 23:21; UTC

News

Incyte Corp shares are lower in after-market trading, continuing a trend of four consecutive sessions finishing down amid rising Treasury yields and mixed ESMO data sentiment.

2026-08-27 20:07; UTC

News

Incyte Corp shares are lower today, reflecting broader market declines. Analysts from TD Cowen upgraded the stock to a strong buy amid ongoing positive sentiment.

2026-08-26 19:36; UTC

Incyte Corp shares are lower during Wednesday's session, having reached a session low earlier. No specific news was identified to explain the price movement.

2026-08-25 23:21; UTC

Incyte Corp. shares are trading roughly flat in after-market hours. Market sentiment is influenced by a decline in crude oil prices and easing treasury yields.

2026-08-24 23:01; UTC

Incyte Corp shares are higher in after-market trading, significantly above their 20-day moving average and near the upper end of their one-month range.

2026-08-21 19:46; UTC

News

Incyte Corp's stock is higher today, supported by President Pablo J. Cagnoni's recent sale of 10,801 shares at $125.56. The stock remains near its one-month high.

2026-08-20 23:41; UTC

Incyte Corp shares are higher in after-market trading, recovering from a slight dip and positioned above the 20-day moving average. No specific news was identified.

2026-08-19 23:01; UTC

Incyte Corp shares declined in after-hours trading, pulling back from earlier gains. The stock remains above its 20-day moving average and near a one-month high.

2026-08-17 20:06; UTC

News

Piper Sandler raised Incyte Corp's price target to $130 from $110, contributing to the stock's upward movement after four days of declines.

2026-08-14 19:36; UTC

Incyte Corp shares are lower, continuing a recent decline amid concerns over July retail sales, which fell 0.6% against expectations for growth.

2026-08-13 23:26; UTC

Incyte Corp shares are lower in after-market hours, despite broader market gains from reduced Federal Reserve rate hike expectations. No specific news was identified.

2026-08-10 19:36; UTC

Incyte Corp shares are higher today, maintaining an upward trend since Friday. The stock remains above its 20-day moving average, reflecting solid performance.

2026-08-06 19:44; UTC

Incyte Corp shares are lower amid broader biotechnology sector declines. The stock is trading near the lower end of its one-month range.

2026-08-05 19:56; UTC

Incyte Corp shares are lower today, retracing from earlier session gains. No specific news was identified to explain the decline.

2026-08-04 19:46; UTC

News

Mizuho raised its price target on Incyte Corp to $137, maintaining an Outperform rating. Analyst Josh Brown's comments on CNBC contributed to positive sentiment today.

2026-08-03 23:56; UTC

Incyte Corp shares are higher in after-market hours, recovering from five consecutive daily declines. Broader market sentiment remains positive amid declining oil prices.

2026-07-31 22:21; UTC

Incyte Corp's shares are higher in after-market trading, driven by a rise in the Biotechnology sub-sector. The stock remains above its 20-day moving average.

2026-07-30 23:56; UTC

Incyte Corp shares are lower in after-market trading, continuing a trend of declines since Thursday's close amid broader market pressures.

2026-07-29 22:51; UTC

Event

Incyte Corp shares are higher after the European Commission approved Opzelura® for moderate atopic dermatitis treatment. Market conditions are also advancing in after-market trading.

Akcijų palyginimas

Kainos pokytis

Incyte Corp Prognozė

Kainos tikslas

By TipRanks

7.43% į viršų

12 mėnesių prognozė

Vidutinis 130.789 USD  7.43%

Aukščiausias 155 USD

Žemiausias 104 USD

Remiantis 21 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Incyte Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

21 ratings

11

Pirkti

10

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

267 / 339 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
help-icon Live chat